Purified Cannabidiol for Treatment of Refractory Epilepsies in Pediatric Patients with Developmental and Epileptic Encephalopathy

  • Nicola Pietrafusa
  • Alessandro Ferretti
  • Marina Trivisano
  • Luca de Palma
  • Costanza Calabrese
  • Giusy Carfì Pavia
  • Ilaria Tondo
  • Simona Cappelletti
  • Federico Vigevano
  • Nicola SpecchioEmail author
Short Communication



A pharmaceutical grade formulation of cannabidiol (CBD) has been approved for the treatment of Dravet syndrome and Lennox-Gastaut syndrome; however, this formulation is not yet available to patients outside the USA. In addition, CBD is thought to have broad anti-seizure properties that may be beneficial for other types of intractable epilepsy.


The aim of this study was to evaluate the efficacy, safety and tolerability of artisanal medical CBD oil in patients with developmental and epileptic encephalopathy (DEE) at the tertiary epilepsy center of Bambino Gesù Children’s Hospital in Rome, Italy.


This was a single-center, prospective, open-label study. Patients aged from 1 to 18 years with DEE and seizures refractory to appropriate antiepileptic drugs (AEDs) and other alternative treatments (i.e., vagal nerve stimulator and ketogenic diet) were included. Crystalline extract CBD powder (98–99% pure) in an oil artisanal formulation was added to the baseline AED regimen at a dosage of 2–5 mg/kg/day divided for twice-daily administration, then up-titrated until intolerance or a maximum dosage of 25 mg/kg/day was reached. Patients were treated for at least 6 months. Efficacy, safety and tolerability of CBD treatment were assessed through the evaluation of seizure frequency and reports of adverse effects.


Twenty-nine patients were enrolled in this study (41.4% male). The mean duration of exposure to artisanal CBD was 11.2 months [range 6–25 months; standard deviation (SD) ± 4.4 months]. Mean age at study enrollment was 9.3 years (range 1.9–16.3 years; SD ± 4.7 years). Eleven out of 29 patients (37.9%) had a ≥ 50% improvement in seizure frequency; one patient became seizure free. None of the patients reported worsening seizure frequency; however, 18 patients (62.1%) experienced no beneficial effect regarding seizure frequency. Adverse effects were reported in seven patients (24.14%), most commonly somnolence, decreased appetite and diarrhea. Adverse events were mild and transient, and no dose modification of CBD or other AEDs was required.


These data suggest that CBD may have beneficial effects in patients with DEE and an acceptable safety profile. Placebo-controlled randomized trials should be conducted to formally assess the safety and efficacy of CBD in patients with DEE.


Compliance with Ethical Standards


This study was not funded.

Conflict of Interest

Nicola Pietrafusa, Alessandro Ferretti, Marina Trivisano, Luca de Palma, Costanza Calabrese, Giusy Carfi’ Pavia, Ilaria Tondo, Simona Cappelletti, Federico Vigevano, and Nicola Specchio have no conflicts of interest.

Ethical Approval

This trial was conducted in accordance with International Conference on Harmonization Good Clinical Practice guidelines and ethical principles that have their origin in the Declaration of Helsinki.

Informed Consent

Written informed consent was obtained from each patient’s parent or primary caregiver before any trial-related procedures were performed.


  1. 1.
    Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology. Epilepsia. 2017;58(4):512–21.CrossRefGoogle Scholar
  2. 2.
    McTague A, Howell KB, Cross JH, Kurian MA, Scheffer IE. The genetic landscape of the epileptic encephalopathies of infancy and childhood. Lancet Neurol. 2016;15(3):304–16.CrossRefGoogle Scholar
  3. 3.
    Donat JF. The age-dependent epileptic encephalopathies. J Child Neurol. 1992;7(1):7–21.CrossRefGoogle Scholar
  4. 4.
    Berg AT, Zelko FA, Levy SR, Testa FM. Age at onset of epilepsy, pharmacoresistance, and cognitive outcomes: a prospective cohort study. Neurology. 2012;79(13):1384–91.CrossRefGoogle Scholar
  5. 5.
    Jones NA, Hill AJ, Smith I, Bevan SA, Williams CM, Whalley BJ, et al. Cannabidiol displays. Antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther. 2010;332(2):569–77.CrossRefGoogle Scholar
  6. 6.
    Jones NA, Glyn SE, Akiyama S, Hill TD, Hill AJ, Weston SE, et al. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure. 2012;21(5):344–52.CrossRefGoogle Scholar
  7. 7.
    Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15(3):270–8.CrossRefGoogle Scholar
  8. 8.
    Hess EJ, Moody KA, Geffrey AL, Pollack SF, Skirvin LA, Bruno PL, et al. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia. 2016;57(10):1617–24.CrossRefGoogle Scholar
  9. 9.
    Gofshteyn JS, Wilfong A, Devinsky O, Bluvstein J, Charuta J, Ciliberto MA, et al. Cannabidiol as a potential treatment for febrile infection-related epilepsy syndrome (FIRES) in the acute and chronic phases. J Child Neurol. 2017;32(1):35–40.CrossRefGoogle Scholar
  10. 10.
    GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences announce FDA approval of EPIDIOLEX® (cannabidiol) oral solution—the first plant-derived cannabinoid prescription medicine. Accessed 15 Nov 2018.
  11. 11.
    Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome Neurology. N Engl J Med. 2018;378(20):1888–97.CrossRefGoogle Scholar
  12. 12.
    Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, et al. CBD in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085–96.CrossRefGoogle Scholar
  13. 13.
    Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. Cannabidiol in Dravet syndrome study group. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011–20.CrossRefGoogle Scholar
  14. 14.
  15. 15.
    GW Pharmaceuticals announces the European Medicines Agency (EMA) accepts Epidiolex® (cannabidiol) Marketing Authorization Application (MAA) for review. Accessed 1 Nov 2018.
  16. 16.
    Citti C, Ciccarella G, Braghiroli D, Parenti C, Vandelli MA, Cannazza G. Medicinal cannabis: Principal cannabinoids concentration and their stability evaluated by a high performance liquid chromatography coupled to diode array and quadrupole time of flight mass spectrometry method. J Pharm Biomed Anal. 2016;128:201–9.CrossRefGoogle Scholar
  17. 17.
    Pacifici R, Marchei E, Salvatore F, Guandalini L, Busardò FP, Pichini S. Evaluation of cannabinoids concentration and stability in standardized preparations of cannabis tea and cannabis oil by ultra-high performance liquid chromatography tandem mass spectrometry. Clin Chem Lab Med. 2017;55(10):1555–63.CrossRefGoogle Scholar
  18. 18.
    Calvi L, Pentimalli D, Panseri S, Giupponi L, Gelmini F, Beretta G, Vitali D. Comprehensive quality evaluation of medical Cannabis sativa L. inflorescence and macerated oils based on HS-SPME coupled to GC–MS and LC–HRMS (q-exactive orbitrap®) approach. J Pharm Biomed Anal. 2018;150:208–19.CrossRefGoogle Scholar
  19. 19.
    Carcieri C, Tomasello C, Simiele M, De Nicolò A, Avataneo V, Canzoneri L. Cannabinoids concentration variability in cannabis olive oil galenic preparations. J Pharm Pharmacol. 2018;70(1):143–9.CrossRefGoogle Scholar
  20. 20.
    Decreto 9 novembre 2015: Funzioni di Organismo statale per la cannabis previsto dagli articoli 23 e 28 della convenzione unica sugli stupefacenti del 1961, come modificata nel 1972. Available online: Molecules 2018, 23, 1230 21 of 22.;jsessionid=p1rnwNujUKlqQ5azhA%20Q95A__.ntc-as3-guri2. Accessed 1 Oct 2018.
  21. 21.
    Pamplona FA, da Silva LR, Coan AC. Potential clinical benefits of CBD-rich cannabis extracts over purified CBD in treatment-resistant epilepsy: observational data meta-analysis. Front Neurol. 2018;9:759.CrossRefGoogle Scholar
  22. 22.
    Neubauer D, Perković Benedik M, Osredkar D. Cannabidiol for treatment of refractory childhood epilepsies: experience from a single tertiary epilepsy center in Slovenia. Epilepsy Behav. 2018;81:79–85.CrossRefGoogle Scholar
  23. 23.
    Porcari GS, Fu C, Doll ED, Carter EG, Carson RP. Efficacy of artisanal preparations of Cannabidiol for the treatment of epilepsy: practical experiences in a tertiary medical center. Epilepsy Behav. 2018;80:240–6.CrossRefGoogle Scholar
  24. 24.
    Pavlovic R, Nenna G, Calvi L, Panseri S, Borgonovo G, Giupponi L, et al. Quality traits of “CBD oils”: cannabinoids content, terpene fingerprint and oxidation stability of European commercially available preparations. Molecules. 2018;23:5.CrossRefGoogle Scholar
  25. 25.
    Tzadok M, Uliel-Siboni S, Linder I, Kramer U, Epstein O, Menascu S, et al. CBD-enriched medical cannabis for intractable pediatric epilepsy: the current Israeli experience. Seizure. 2016;35:41–4.CrossRefGoogle Scholar
  26. 26.
    Hausman-Kedem M, Menascu S, Kramer U. Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents—an observational, longitudinal study. Brain Dev. 2018;40(7):544–51.CrossRefGoogle Scholar
  27. 27.
    Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav. 2013;29(3):574–7.CrossRefGoogle Scholar
  28. 28.
    Fusco L, Vigevano F. Tonic spasm seizures: a particular and previously unreported type of seizure. Epilepsia. 1994;35(7):S87.Google Scholar
  29. 29.
    Hussain SA, Zhou R, Jacobson C, Weng J, Cheng E, Lay J. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and Lennox-Gastaut syndrome. Epilepsy Behav. 2015;47:138–41.CrossRefGoogle Scholar
  30. 30.
    Trial of cannabidiol (CBD; GWP42003-P) for infantile spasms (GWPCARE7). Accessed on 1 Jan 2018.
  31. 31.
    Wang GS. Pediatric concerns due to expanded cannabis use: unintended consequences of legalization. J Med Toxicol. 2017;13(1):99–105.CrossRefGoogle Scholar
  32. 32.
    Rosenberg EC, Louik J, Conway E, Devinsky O, Friedman D. Quality of life in childhood epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with CBD. Epilepsia. 2017;58(8):96–100.CrossRefGoogle Scholar
  33. 33.
    Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246–51.CrossRefGoogle Scholar
  34. 34.
    Taylor L, Gidal B, Blakey G, Tayo B, Morrison G. A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs. 2018;32(11):1053–67.CrossRefGoogle Scholar
  35. 35.
    Montouris GD, Wheless JW, Glauser TA. The efficacy and tolerability of pharmacologic treatment options for Lennox-Gastaut syndrome. Epilepsia. 2014;55(Suppl 4):10–20.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Nicola Pietrafusa
    • 1
  • Alessandro Ferretti
    • 1
  • Marina Trivisano
    • 1
  • Luca de Palma
    • 1
  • Costanza Calabrese
    • 1
  • Giusy Carfì Pavia
    • 1
  • Ilaria Tondo
    • 1
  • Simona Cappelletti
    • 1
  • Federico Vigevano
    • 2
  • Nicola Specchio
    • 1
    Email author
  1. 1.Rare and Complex Epilepsy Unit, Division of Neurology, Department of NeurosciencesBambino Gesù Children’s Hospital, IRCCSRomeItaly
  2. 2.Department of NeuroscienceBambino Gesù Children’s Hospital, IRCCSRomeItaly

Personalised recommendations